ArticleScientific reports2026
Pharmacological evaluation of a Brucine-loaded nanoemulgel for enhanced wound healing through in-silico and in-vivo investigations.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wound healing is a vital biological process that restores damaged tissue. In diabetes, this process slows down due to chronic inflammation and oxidative stress. Brucine, a natural compound from Nux vomica, is known for its anti-inflammatory and antioxidant actions and its ability to promote fibroblast growth. However, its poor solubility and toxicity limit its clinical use. To address these issues, a nanoemulgel formulation was developed to improve the delivery and wound-healing effectiveness of brucine. The study aimed to develop and evaluate a brucine-loaded nanoemulgel for wound healing. The objectives were to (i) study molecular interactions of brucine with wound-healing proteins using in-silico analysis, (ii) prepare and characterize the nanoemulgel, and (iii) test its wound-healing ability in diabetic rats. Molecular docking was performed using AutoDock 4.1 to predict brucine's binding with proteins involved in fibroblast proliferation and tissue repair. The nanoemulgel was prepared by incorporating brucine-loaded nanoemulsion into a hydrogel base. Its drug release, skin permeation, and stability were tested using standard laboratory techniques. Wound healing was evaluated in streptozotocin-induced diabetic rats by measuring wound closure over 14 days and analyzing tissue samples microscopically. Docking results showed strong binding of brucine with fibroblast growth factor receptor (FGFR, - 9.63 kcal/mol) and epidermal growth factor receptor (EGFR, - 9.17 kcal/mol), indicating its potential to stimulate cell growth and repair. The nanoemulgel showed 1.8-fold higher drug permeation and controlled release up to 12 h compared to plain gel. In diabetic rats, wounds treated with brucine nanoemulgel showed 80% closure by day 14, compared to 65% with standard treatment and 40% in untreated controls. Histopathology confirmed better collagen formation, fibroblast proliferation, and reduced inflammation. The brucine-loaded nanoemulgel improved drug delivery and significantly accelerated diabetic wound healing. It enhanced fibroblast activity and tissue repair while minimizing inflammation. This nanoformulation offers a promising topical strategy for chronic wound management, warranting further stability and clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.